Company news

Median Technologies news in 2026

Median Technologies's news releases, calls and decks from 2026, newest first.

View company

Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ESMO 2026

October 20, 2026

Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York

October 19, 2026

eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026

October 13, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30, 2026

October 11, 2026

Median Technologies Secures One of the Largest iCRO Projects in Its History

September 15, 2026

Median Technologies: H2 2026 Financial Communication Calendar

September 10, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of August 31, 2026

September 8, 2026

Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis Pan-Cancer Strategy

September 3, 2026

Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy

September 2, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2026

August 10, 2026

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

July 30, 2026

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

July 22, 2026

Half Year Median Technologies liquidity contract statement – First half of 2026

July 15, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

July 6, 2026

Median Technologies’ eyonis® LCS Obtains CE Marking

July 3, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

June 8, 2026

Median Technologies Announces Successful Upsized Capital Increase of € 50 Million

June 3, 2026

Median Technologies Brings Forward Subscription Period of its €50 Million Capital Increase on the Back of Strong Demand from Institutional Investors

June 1, 2026

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis®...

May 27, 2026

Median Technologies to Showcase iCRO’s Central and AI-powered Imaging Services for Oncology Clinical Trials at ASCO 2026

May 26, 2026

Management Report of the Board of Directors – Financial Year Ended on Dec 31, 2025 – OEGM dated June 10, 2026

May 21, 2026

Median Technologies Announces the Availability of the Preparatory Documents for the Annual Shareholders’ Ordinary and Extraordinary General Meeting on June 10, 2026

May 21, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2026

May 4, 2026

Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights

April 23, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2026

April 7, 2026

Median Technologies Achieves ISO 13485: 2016 Certification for eyonis® Medical Device Quality Management System

March 18, 2026

Median Technologies Meets the Eligibility Conditions for the PEA-PME Scheme

March 13, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2026

March 9, 2026

Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology

March 2, 2026

Median Technologies to present at the TD Cowen 46th Annual Health Care Conference

February 27, 2026

Median Technologies to Host Webcasts Highlighting Strategic Advances Driving U.S. Deployment of eyonis® LCS

February 23, 2026

FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

February 18, 2026

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

February 12, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31, 2026

February 11, 2026

Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening

February 9, 2026

Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026

January 19, 2026

Median Technologies: H1 2026 Financial Communication Calendar

January 14, 2026

Half Year Median Technologies Liquidity Contract Statement

January 7, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31, 2025

January 5, 2026

Decks in 2026